Table 2.
Short-term toxicities of CAR-T infusion.
| Variable | P1 | P2 | P3 |
|---|---|---|---|
| Treatment | CAR-T therapy | CAR-T therapy | ASCT bridging CAR-T therapy |
| CRS | 1 | 0 | 2 |
| ICANS | 0 | 0 | 0 |
| Fever | Yes | None | Yes |
| Hypotension | None | None | None |
| Hypoxemia | None | None | Low-flow oxygen |
| ALT/AST ≥ 3 ULT | None | None | Yes |
| Total bilirubin ≥ 2 ULT | None | None | None |
| Albumin<lb g/L | None | None | None |
| Prolonged coagulation | None | None | None |
| Hematologic toxicity | Grade 4 | Grade 4 | Grade 4 |
| IL-6 max/baseline | 20.6 | 2.2 | 150.7 |
| Other short-term toxicities | None | None | Gastrointestinal mucositis; upper gastrointestinal hemorrhage |
CAR-T, chimeric antigen receptor T cell; ASCT, autologous stem cell transplantation; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.